CN108392482B - β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury - Google Patents

β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury Download PDF

Info

Publication number
CN108392482B
CN108392482B CN201810178801.5A CN201810178801A CN108392482B CN 108392482 B CN108392482 B CN 108392482B CN 201810178801 A CN201810178801 A CN 201810178801A CN 108392482 B CN108392482 B CN 108392482B
Authority
CN
China
Prior art keywords
radiation
mice
fapm
irradiation
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810178801.5A
Other languages
Chinese (zh)
Other versions
CN108392482A (en
Inventor
余祖胤
邢爽
申星
熊国林
从玉文
王芳敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CN202010063267.0A priority Critical patent/CN111388474B/en
Priority to CN201810178801.5A priority patent/CN108392482B/en
Publication of CN108392482A publication Critical patent/CN108392482A/en
Application granted granted Critical
Publication of CN108392482B publication Critical patent/CN108392482B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Abstract

The invention relates to a compound with radiation damage resistance shown in a general formula I, an isomer thereof, and application of a pharmaceutical composition containing the compound and the isomer thereof in preparing medicines for preventing or treating acute radiation sickness, nuclear and radiation damage caused by tumor radiotherapy, or application of the pharmaceutical composition as a tool medicine for researching radiation damage resistance.

Description

β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of β -methoxy acrylate compounds in preparation of medicines for preventing and/or treating radiation injury.
Background
The nuclear energy and nuclear technology are increasingly widely applied in various fields such as industrial and agricultural production, medical treatment and health, scientific research, national defense industry and the like, and have potential threats while bringing great benefits to human beings. Nuclear leakage of nuclear power stations caused by nuclear warfare, nuclear terrorist attack, earthquakes or tsunamis and the like, and personnel can be irradiated by rays due to poor management or misoperation in the work of civil radioactive sources, medical irradiation and the like. Acute Radiation Sickness (ARS), or collectively referred to as Acute Radiation damage Syndrome (ARS), occurs when the body is irradiated with a large dose (>1Gy) of ionizing Radiation over a short period of time. Acute radiation disease is a systemic disease, which is divided into three types, namely, marrow type, intestinal type and brain type, according to different damaged organs; radiation sickness can be classified into acute, subacute and chronic according to the length of exposure time. The death rate of acute radiation diseases is high, the cure is difficult, and the prior case of saving lives of patients with the radiation dose of more than 8Gy does not exist at present. In addition, during the course of radiation therapy, the tumor cells are killed by the radiation and the normal cells are damaged, which often limits the practical application of radiation therapy. Therefore, in order to provide safety for efficient application of nuclear energy and nuclear technology against radiation damage, there is a need for vigorous development of radiation damage resistant medical technology.
β -methoxy acrylic ester is a new bactericide, mainly used for killing fungi in agriculture (such as grains, fruits and vegetables) by mixing with Q of cytochrome b0The combination of the sites blocks the electron transfer and proton transfer between cytochrome b and cytochrome c1, thereby inhibiting the respiration of mitochondria, blocking the synthesis of ATP, and stopping the energy circulation, thereby playing a broad-spectrum sterilization role. The compounds were first natural products, such as strobilurins, which are simplest strobilurin A (Strobilurin). Thereafter, successively, chemically synthesized products such as fenamidopropyl (Azoxystrobin) and Picoxystrobin (Picoxystrobin), and Fluacrypyrim (FAPM) and the like appear.
Disclosure of Invention
The invention aims to provide a new application of β -methoxy acrylic ester compounds in medicaments.
The new application of the β -methoxy acrylate compound in the preparation of the product is the application of the β -methoxy acrylate compound in the preparation of the product, wherein the function of the product is as follows (a1) and/or (a2) and/or (a3) and/or (a4) and/or (a5) and/or (a6) and/or (a 7):
(a1) preventing or/and treating acute radiation sickness caused by various reasons, such as mild myelogenous acute radiation sickness, moderate myelogenous acute radiation sickness, severe myelogenous acute radiation sickness, extremely severe myelogenous acute radiation sickness and intestinal radiation sickness;
(a2) preventing and/or treating bone marrow suppression caused by various radiation;
(a3) preventing and/or treating bone marrow suppression caused by tumor radiotherapy;
(a4) prevention or/and treatment of myelosuppression caused by radiotherapy combined with chemotherapy or surgery;
(a5) preventing or/and treating nuclear and radiation damage;
(a6) preventing and/or treating radiation damage of normal tissue cells caused by tumor radiotherapy;
(a7) as a tool medicine for researching the radiation damage resistance.
In the application, the β -methoxy acrylate compound is a compound shown in a formula I or an isomer thereof.
Figure BDA0001588115160000021
Wherein:
R1represents phenoxy, substituted phenoxy, heteroaryloxy, substituted heteroaryloxy;
wherein the heteroaromatic ring of the heteroaryloxy group may be a 5-to 6-membered monocyclic or fused ring aromatic group containing at least one heteroatom selected from N, O and S, such as pyrimidinyl, and the substituents of each substituent-bearing group may be selected from halogen, hydroxy, cyano, nitro, aryloxy, C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylthio, mono-, di-or trihalogenated C1-6Alkyl, amino, C1-6Alkylamino radical, C1-10Hydrocarbon acyloxy, C1-10Hydrocarbon amide group, C6-10Aroyloxy radical or C6-10An aromatic amide group;
R2is C1-C6A hydrocarbyl group; r3Is C1-C6An alkyl group;
n is 0 or 1.
Specifically, the compound shown in the formula I can be Fluacrypyrim (FAPM) or Azaxystrobin (AZO).
The compounds of formula I may exist as cis/trans isomers, and the present invention relates to the cis form and the trans form and mixtures of these forms. If desired, the single stereoisomers may be prepared by resolution of a mixture according to conventional methods, or by, for example, stereoselective synthesis. The invention also relates to tautomeric forms of the compounds of the formula I, if motorized hydrogen atoms are present.
The present invention therefore also relates to pharmaceutical compositions containing as active ingredient an effective dose of at least one compound of formula I, or a pharmaceutically acceptable salt and/or stereoisomer thereof, together with conventional pharmaceutical excipients or adjuvants.
The pharmaceutical compositions according to the invention generally contain 0.1 to 90% by weight of a compound of the formula I and/or a physiologically acceptable salt thereof.
The pharmaceutical compositions may be prepared according to methods known in the art. For this purpose, the compounds of the formula I and/or stereoisomers can, if desired, be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants in a suitable administration form or dosage form for human use.
The compound of formula I or the pharmaceutical composition containing it of the present invention can be administered in unit dosage form, either enterally or parenterally, such as orally, intramuscularly, subcutaneously, nasally, oromucosally, dermally, peritoneally or rectally, etc. The administration dosage forms include tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, liposome, transdermal agent, buccal tablet, suppository, lyophilized powder for injection, etc. Can be common preparation, sustained release preparation, controlled release preparation and various microparticle drug delivery systems.
In order to prepare the unit dosage form into tablets, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate and the like; wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrating agents such as dried starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, sodium dodecylsulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cacao butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium salts, sodium lauryl sulfate and the like; lubricants, for example, talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets.
For making the administration units into pills, a wide variety of carriers well known in the art can be used. Examples of the carrier are, for example, diluents and absorbents such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc and the like; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfate, methylcellulose, ethylcellulose, etc.
For making the administration unit into a suppository, various carriers well known in the art can be widely used. As examples of the carrier, there may be mentioned, for example, polyethylene glycol, lecithin, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides and the like. To encapsulate the dosage unit, the active ingredient compound of formula I or a stereoisomer thereof is mixed with the various carriers mentioned above and the mixture thus obtained is placed in hard gelatin capsules or soft gelatin capsules. Or making the effective component of formula I or its stereoisomer into microcapsule, suspending in aqueous medium to form suspension, or making into hard capsule or injection.
For preparing the administration unit into preparations for injection, such as solutions, emulsions, lyophilized powders and suspensions, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, and the like. In addition, for the preparation of isotonic injection, sodium chloride, glucose or glycerol may be added in an appropriate amount to the preparation for injection, and conventional cosolvents, buffers, pH adjusters and the like may also be added.
In addition, colorants, preservatives, flavors, flavorings, sweeteners or other materials may also be added to the pharmaceutical preparation, if desired.
The dosage of a compound of formula I or an isomer thereof according to the present invention to be administered depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight and individual response of the patient or animal, the particular compound used, the route of administration and the frequency of administration, etc. The above-mentioned dosage may be administered in a single dosage form or divided into several, e.g. two, three or four dosage forms.
Drawings
Figure 1 shows the effect of β -methoxy acrylate compound incubation in vitro on apoptosis of bone marrow cells in mice irradiated with 6.5Gy γ -rays ×. ### vs Con group, P <0.01, ### # vs IR group, P <0.01.
FIG. 2 is a graph of the effect of FAPM in vitro incubation on apoptosis of hematopoietic stem progenitor cells in bone marrow cells irradiated with 6.5Gy gamma radiation. Group of Con, P<0.01,##Comparison of IR group, P<0.01,#P<0.05.
FIG. 3 is a graph showing the effect of prophylactic administration of FAPM on apoptosis of hematopoietic stem progenitor cells in bone marrow of mice irradiated with 6.5Gy gamma rays.
Figure 4 is a graph of the effect of prophylactic administration of FAPM on survival of gamma-irradiated mice.
FIG. 5 is a graph showing the effect of prophylactic administration of FAPM on the peripheral blood image of mice irradiated with 6.5Gy gamma radiation. P <0.05, P <0.01 for the IR group.
FIG. 6 is a graph of the effect of prophylactic administration of FAPM on the number of hematopoietic stem and progenitor cells in acutely irradiated mice. P <0.01, P < 0.001.
FIG. 7 is a graph of the effect of prophylactic administration of FAPM on the ability to form colonies of bone marrow cells in 6.5Gy irradiated mice. P <0.05, P <0.01 for the IR group.
Fig. 8 is a graph of the effect of FAPM prophylactic administration on hematopoietic stem cell reconstitution capacity in irradiated mice. P <0.05, P < 0.001.
Fig. 9 shows the therapeutic effect of FAPM post-irradiation administration on acutely irradiated mice. A, 8.5Gy gamma ray irradiation mouse survival curve; BCD, 6.5Gy gamma irradiation mouse hemogram, B platelets, C red blood cells, D hemoglobin.
Detailed Description
The present invention will be described below with reference to specific examples, but the present invention is not limited thereto.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, biomaterials, etc. used in the following examples are commercially available unless otherwise specified.
The present specification discloses methods for preventing and/or treating ionizing radiation damage.
Populations in need thereof include those likely to be susceptible to radiation exposure, such as nuclear weapons attacks, nuclear warfare terrorism attacks, or to enter radiation contaminated areas, which are protected from such radiation exposure by receiving an effective amount of β -strobilurin compounds, isomers thereof, and pharmaceutical compositions containing them within the days or at least hours prior to (likely) radiation exposure.
Individuals in need thereof include injured or ill patients who have been exposed to doses of radiation that may cause hematopoietic damage, and are treated with an effective amount of the β -methoxy acrylate compound, isomers thereof, and pharmaceutical compositions containing them immediately, hours, or at least 1 day after exposure.
The present specification also discloses methods of treating myelosuppression caused by radiation therapy.
Radiotherapy (radiotherapy) and radiotherapy (photothermal) are used interchangeably herein and include external irradiation (external irradiation) and internal irradiation (internal irradiation), also referred to as brachytherapy (brachythermotherapy), intracavitary brachytherapy (intracavitary brachythermology), or interstitial brachythermology (interbody brachythermology). Radiation sources that may be considered include pure Gamma (pure Gamma), pure Beta (pure Beta), and mixed radiation.
As used herein, the terms "chemotherapy" and "chemotherapeutic agent" are used interchangeably and mean a chemotherapeutic agent or drug that exhibits an anti-cancer effect and is used in the treatment of malignancies.
As used herein, radiation-induced myelosuppression includes radiation damage caused by total body irradiation or local irradiation of the chest, lung, pelvis, trunk, etc. Irradiation often causes acute radiation sickness or myelosuppression. Symptoms may include emesis, hematopoietic cytopenia, anemia, thrombocytopenia, leukopenia, hematopoietic cell proliferation disorders, thrombocytopenic hemorrhage, and the like.
The present invention is also directed to methods of preventing and/or treating an individual in need thereof (e.g., mammal, human, horse, dog, cat) with β -methoxy acrylate compounds, isomers thereof, and pharmaceutical compositions containing them the identification of an individual as to whether such treatment is needed can be made at the discretion of the individual itself or a health care radiation protection professional and can be subjective (e.g., opinion) or objective (e.g., measurable by test or diagnostic methods).
Individuals in need thereof include those who will receive radiation therapy, whether radiation therapy alone or in combination with other chemotherapeutic agents that may result in myelosuppression. This need may manifest itself before the individual receives radiation therapy, chemotherapy, or a combination of therapy(s); the subject is receiving radiation therapy, chemotherapy, or a combination of therapy(s); the subject is receiving radiation therapy, chemotherapy, or a combination of therapy(s). For example, an individual may be about to, or may have received radiation therapy in combination with chemotherapy.
As used herein, a therapeutically effective amount means an amount effective to provide a therapeutic benefit (such as an improvement in symptoms), for example, an amount effective to ameliorate symptoms of anemia, when administered to a human or non-human subject.
According to certain embodiments, the β -methoxy acrylate compounds, their isomers, and pharmaceutical compositions containing them may be used in a variety of treatment regimens, which may vary depending on the individual and the type of treatment.
β -methoxy acrylate compounds, isomers thereof, and pharmaceutical compositions containing them are administered before, during, and/or after treatment, for example, at least one day prior to the subject's first dose of radiation therapy, during radiation therapy, at least one day after cessation of radiation therapy.
The β -methoxyacrylate compound, its isomer, and pharmaceutical compositions containing them are preferably administered before, during, and after myelosuppressive therapy.
According to specific embodiments, β -strobilurin compounds may be administered in combination with other compounds, such as chemotherapeutic agents, anti-inflammatory agents, antipyretics, radiosensitizers, radioprotectants, urinary tract agents, antiemetics, and/or antidiarrheals, for example, cisplatin (cissplatin), carboplatin (carboplatin), docetaxel (docetaxel), paclitaxel (paclitaxel), fluorouracil (flurouroracil), capecitabine (capecitabine), gemcitabine (gelncitabine), irinotecan (irinotecan), topotecan (topotecan), etoposide (etoposide), mitomycin (mitomycin), gefitinib (geftirinib), vincristine (vinblastine), vinblastine (vinblastine), doxorubicin (doxorubin), cyclophosphamide (cyproconazole), oxypredetasone), oxyphenbutazone (oxyphenbutazone), oxyphenbutazone (oxyphenbutazone), oxyphenbutazone (oxyphenbutazone), triamcinoxazone (oxyphenbutazone), triamcinoxazone (doxfenazone), triamcinoxazone (doxestrene (doxestrin), triamcinoxazone (doxestre), triamcinoxazone (doxestrin), triamcinoxazone (doxestrin.
The methods disclosed herein also provide for administering a therapeutically effective amount of β -methoxy acrylate compound to a subject in need thereof to protect the subject against systemic damage caused by radiation.
Examples 1, β -Methoxyacrylate Compounds for inhibiting apoptosis of hematopoietic cells induced by radiation
(1) β -methoxyl acrylate compound can reduce the mouse marrow karyocyte apoptosis caused by gamma ray irradiation obviously.
To investigate the effect of β -methoxy acrylate compounds on the radiation-induced apoptosis of hematopoietic cells in mouse bone marrow, the inventors selected β -methoxy acrylate compounds Fluacrypyrim (FAPM) and Azoxystrobin (AZO) for experiments57The bone marrow cells of the femur were harvested after cervical dislocation of BL/6J mice and Bone Marrow Nucleated Cells (BMNCs) were isolated for the experiment. BMNCs are divided into normal control (Con), normal + dosing group (Con + X), irradiation control (IR) and irradiation control + dosing group (IR + X), where X represents the drug used, here FAPM and AZO, respectively. Wherein the cells of the IR group and IR + X group were irradiated with 6.5Gy gamma rays, the cells of the Con group and Con + X group were subjected to pseudo irradiation, and the cells of the Con + X and IR + X groups were added with drug X1 hour before irradiation and cultured in an incubator at 37 ℃ for 1 hour. And (3) after irradiation (pseudo irradiation), putting the cells back to the incubator at 37 ℃ for culture, collecting the cells after 9h, and detecting the apoptosis rate of the cells by flow cytometry after Annexin V and PI labeling. The experiment was repeated three times.
As a result, the apoptosis rate of BMNCs is remarkably increased after 9h of gamma-ray irradiation of 6.5Gy, while the BMNCs of mice incubated with FAPM of 5 μ M or AZO of 30 μ M can remarkably reduce apoptosis caused by gamma-ray irradiation of 6.5Gy after 1h of BMNCs (figure 1).
(2) β -methoxyl acrylate compound FAPM in vitro incubation obviously reduces the apoptosis of hematopoietic stem progenitor cells in mouse bone marrow caused by gamma ray irradiation.
On the basis of the above experiments, one of the compounds FAPM is selected to carry out a verification experiment. BMNCs collection methods are as above for the groups. Cells were harvested at 9h post-irradiation and hematopoietic stem and progenitor cells were differentiated by Lin FITC, c-kit APC and Sca-1PE-Cy7 labeling, apoptotic cells were labeled by Active caspase-3, and the effect of FAPM on apoptosis of hematopoietic stem and progenitor cells in 6.5Gy gamma-irradiated mouse bone marrow nucleated cells was studied. The experiment was repeated three times.
As shown in FIG. 2, FAPM 5. mu.M in vitro incubation of BMNCs for 1h not only significantly reduced the apoptosis of mouse bone marrow nucleated cells caused by 6.5Gy gamma-ray irradiation, but also significantly reduced the apoptosis rate of hematopoietic stem progenitor cells in bone marrow compared with the irradiation control group.
(3) β -methoxy acrylate FAPM administration in vivo significantly reduced gamma irradiation induced apoptosis of hematopoietic stem progenitor cells in mouse bone marrow.
Based on the above research results, in vivo experiments were carried out: 15 male C57BL/6J mice were divided into Normal control (Normal), irradiation control (IR) and FAPM groups of 5 mice each. The IR group and FAPM group mice are irradiated with 6.5Gy gamma rays all over the body. The FAPM group mice are injected with 50mg/kg intraperitoneal once a day 2 days before irradiation, and are continuously administered 3 times (-2d, -1d, -3h), and the control group is irradiated with the injection solvent. The mice are killed by cervical dislocation 6 hours after irradiation, and the apoptosis rate of bone marrow nucleated cells and hematopoietic stem progenitor cells is detected by taking femoral bone marrow cells and marking with antibodies such as Annexin V and the like. As shown in fig. 3, after 6.5Gy gamma irradiation, the apoptosis rates of Bone Marrow Nucleated Cells (BMNCs), hematopoietic stem cells (LSK) and hematopoietic progenitor cells (LK) of the mice in the control group were all significantly increased, while the apoptosis rate of the mice in the FAPM prevention administration group was significantly decreased compared to the control group.
The results show that the β -methoxyl acrylate compound FAPM pretreatment in vitro or preventive administration before irradiation can obviously reduce the apoptosis of mouse marrow nucleated cells, hematopoietic stem cells and hematopoietic progenitor cells caused by radiation irradiation.
Example 2, effect of β -Methoxyacrylate Compounds on survival of mice injured by acute radiation.
β -methoxyl acrylic ester compound FAPM can obviously improve the survival rate of the acute radiation injury mouse.
To investigate the presence or absence of radiation damage resistance of β -methoxy acrylate compounds60Co gamma rayThe experiment is carried out by taking a whole-body irradiated mouse as a model (n is 10), and the research shows that the survival rate of the 8.0Gy whole-body irradiated mouse is improved by 50 percent (100 percent vs.50 percent) and the survival rate of the 8.5Gy whole-body irradiated mouse is improved by 60 percent (60 percent vs.0) by carrying out intraperitoneal injection of 50mg/kg once a day starting 2 days before FAPM irradiation and continuously carrying out administration for 3 times (-2d, -1d, -3h), as shown in figure 4. This indicates that FAPM has significant radioprotective effects in acutely ill mice.
Example 3 Effect of β -Methoxyacrylate Compounds on peripheral blood flow in mice with acute radiation injury
The prophylactic administration of FAPM significantly promotes the recovery of peripheral blood multi-lineage hematopoietic cells in irradiated mice.
To study the effect of FAPM on hematopoietic function in acute radiation-damaged mice, 16 male C were used57BL/6J mice were divided into irradiation control (IR) and FAPM groups of 8 mice each, and the mice were irradiated with 6.5Gy gamma-rays systemically. The FAPM group mice are administered 3 times (-2d, -1d, -3h) once a day starting 2 days before irradiation, and are injected with 50mg/kg of intraperitoneal injection every time, while the control group is irradiated with solvent. Peripheral hemograms were detected at different times before and after irradiation, respectively. As shown in the figure, the peripheral blood cell number and the hemoglobin content of the mice in the control group irradiated after the 6.5Gy gamma ray total body irradiation are gradually and continuously reduced, and the gradual recovery is started 10 to 14 days after the irradiation; the lowest values of platelet, leukocyte, erythrocyte number and hemoglobin content in FAPM administration group are obviously increased compared with the irradiation control group, the recovery time is advanced, and the recovery process is accelerated (figure 5).
Example 4, prophylactic administration of FAPM increases the number of hematopoietic stem progenitor cells in the bone marrow of irradiated mice.
To investigate the effect of FAPM on the number of hematopoietic stem and progenitor cells in irradiated mice, 10C were used57BL/6J mice were divided into irradiation control (IR) and FAPM groups of 5 mice each and the mice were irradiated with 6.5Gy gamma rays systemically. The FAPM group mice are injected with 50mg/kg intraperitoneal once a day 2 days before irradiation, and are continuously administered 3 times (-2d, -1d, -3h), and the control group is irradiated with the injection solvent. The mice are killed by cervical dislocation 10 days after irradiation, and the content of hematopoietic stem and progenitor cells is detected by flow cytometry after the bone marrow nucleated cells of the thighbone are marked by antibodies. The results show that F is 10 days after irradiationBone marrow nucleated cell count and hematopoietic progenitor cells (Lin) of mice in APM administration group-c-kit+Sca-1-) And hematopoietic stem cells (Lin)-c-kit+Sca-1+) The number of the compounds is remarkably increased compared with that of an irradiated control group (P)<0.001), long-term hematopoietic stem cells (Lin) among hematopoietic stem cells-c-kit+Sca-1+Flt3-CD34-) And short-term hematopoietic stem cells (Lin)-c-kit+Sca-1+Flt3-CD34+) The number of the compounds is also obviously increased compared with the control group (P)<0.01), see fig. 6.
Example 5, prophylactic administration of FAPM enhances the colony forming ability of hematopoietic cells in bone marrow of irradiated mice.
In vitro colony formation experiment results show that the capacity of forming colonies by bone marrow nucleated cells 10 days after the irradiation of mice with 6.5Gy gamma rays can be increased by continuously administering FAPM for 3 days before 50mg/kg irradiation. As shown in FIG. 7, the total colony number in FAPM group is significantly increased (P <0.01), wherein the increase in granulocyte macrophage colony (CFU-GM), burst red colony (BFU-E), and mixed colony (CFU-Mix) is significant.
Example 6, prophylactic administration of FAPM enhances the ability of irradiated mice to reconstitute hematopoiesis from bone marrow hematopoietic stem and progenitor cells.
In order to study the effect of FAPM preventive administration on the hematopoietic reconstitution capacity of hematopoietic stem and progenitor cells of mice with acute radiation disease, we developed a bone marrow cell competitive transplantation experiment. Male C57BL/6J mice were divided into Normal control group (Normal), irradiation control (IR) and FAPM administration groups, and the mice in the IR group and FAPM group were all irradiated with 6.5Gy gamma rays systemically at the irradiation dose rate of 61.68 cGy/min. The FAPM group mice are injected with 50mg/kg intraperitoneal once a day 2 days before irradiation, and are continuously administered 3 times (-2d, -1d, -3h), and the control group is irradiated with the injection solvent. Mice were sacrificed by cervical dislocation 10 days after irradiation, and femoral bone marrow nucleated cells were taken as donor cells (CD 45.2)+) (ii) a Another 2 healthy males, CD45.1, were taken+Mouse bone marrow nucleated cells as competitor cells (CD 45.1)+) The two were mixed and injected into recipient mice via tail vein (9.0Gy gamma-ray whole body irradiated CD 45.1)+Mouse), the injection cell volume was 0.3ml, which contained 3X 106The single donor is thinSum of cells 1.5X 105And (4) competing cells. Detection of CD45.1 in peripheral blood cells of recipient mice by flow cytometry at 4, 8, 12 and 16 weeks after competitive transplantation of bone marrow cells, respectively+And CD45.2+Chimerism rate of cells (FIG. 8B). The results are shown in fig. 8C, and the chimerism rate of FAPM-administered mice was significantly higher in the group 4-16 weeks after competitive transplantation than in the irradiated control group. Detection of CD3 in peripheral blood 12 weeks after transplantation+Cell, B220+Cells and Gr-1+CD11b+The cell ratio shows that the cell ratio of each line derived from IR and FAPM group donors has no significant difference, and the suggestion that FAPM administration does not influence the differentiation capability of the mouse bone marrow hematopoietic stem cells. The ratio of hematopoietic stem progenitor cells detected by bone marrow cell flow cytometry of a mouse killed at 16W after transplantation shows that the number of the hematopoietic stem cells in the FAPM group is obviously higher than that in the IR group, which indicates that the self-renewal capacity of the hematopoietic stem cells is enhanced by the FAPM administration. After transplantation, 16W of the receptor mouse bone marrow cells of the IR group and the FAPM group are taken, and CD45.2 is separated by flow cytometry after antibody marking+HSC, which are transplanted secondarily into CD45.1 recipient mice. The survival rate of the receptor mice in 30 days is observed, and the result shows that the survival rate of the receptor mice in the FAPM group is obviously higher than that of the receptor mice in the IR group (see figure 8F), which indicates that the FAPM improves the capacity of the irradiated mice hematopoietic stem cells for long-term hematopoietic reconstitution.
Example 7, β Effect of FAPM on the treatment of mice with acute radiation sickness
In the research, the β -methoxy acrylate compound is found to have obvious radiation protection effect on acute radiation-induced mice by preventing administration for the first time, and on the basis, the treatment effect on the acute radiation-induced mice by administration after FAPM irradiation is further researched by animal experiments.
First, animal survival experiments prove that: the survival rate of the mice irradiated by 8.5Gy gamma rays can be improved by administration after FAPM irradiation. [ 20 Male C57BL/6J mouse Total body irradiation60Co gamma ray 8.5Gy, irradiated mice were randomly divided into irradiation control group (IR) and FAPM treatment groups, each group consisting of 10 mice. Wherein FAPM group mice start to inject FAPM 50mg/kg in abdominal cavity 2h after irradiation, and are continuously injected 7 times once a day, and irradiated control group to inject solvent, and mice survival condition is observed for 30 days. The results are shown in FIG. 9A, FAThe survival rate of the PM treatment group mice is improved by 30 percent compared with that of the irradiation control group. "C (B)
Further examination of the hemograms of the irradiated mice revealed that: after FAPM irradiation, the administration obviously reduces the hematopoietic damage of the mice irradiated by 6.5Gy gamma rays and promotes the recovery of multi-hematopoietic cells. [ 10 Male C ]57BL/6J mouse Total body irradiation60Co gamma ray 6.5Gy, irradiated mice were randomly divided into irradiated control group (IR) and FAPM treated groups, each group consisting of 5 mice. Wherein FAPM mice begin to inject FAPM 50mg/kg in abdominal cavity 2h after irradiation, and are continuously injected 7 times once a day, the control group is irradiated to inject solvent, mouse peripheral hemogram is detected at different time before irradiation and after irradiation respectively, and two groups of differences are compared. The results showed that the decrease of peripheral blood platelet count and red blood cell count was decreased, the lowest value was increased, and the recovery process was accelerated in FAPM group mice compared with IR group (FIGS. 9B-9D).

Claims (2)

1. The application of fluacrypyrim in preparing products; the function of the product is as follows (a1) and/or (a2) and/or (a3) and/or (a4) and/or (a5) and/or (a6) and/or (a 7):
(a1) preventing or/and treating acute radiation sickness caused by various reasons;
(a2) preventing and/or treating bone marrow suppression caused by various radiation;
(a3) preventing and/or treating bone marrow suppression caused by tumor radiotherapy;
(a4) prevention or/and treatment of myelosuppression caused by radiotherapy combined with chemotherapy or surgery;
(a5) preventing or/and treating nuclear and radiation damage;
(a6) preventing and/or treating radiation damage of normal tissue cells caused by tumor radiotherapy;
(a7) as a tool medicine for researching the radiation damage resistance.
2. Use according to claim 1, characterized in that: the acute radiation diseases caused by various reasons comprise mild myelotype acute radiation diseases, moderate myelotype acute radiation diseases, severe myelotype acute radiation diseases, extremely severe myelotype acute radiation diseases and intestinal radiation diseases.
CN201810178801.5A 2018-03-05 2018-03-05 β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury Active CN108392482B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010063267.0A CN111388474B (en) 2018-03-05 2018-03-05 Application of milbexate in preparation of medicine for preventing and/or treating radiation injury
CN201810178801.5A CN108392482B (en) 2018-03-05 2018-03-05 β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810178801.5A CN108392482B (en) 2018-03-05 2018-03-05 β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010063267.0A Division CN111388474B (en) 2018-03-05 2018-03-05 Application of milbexate in preparation of medicine for preventing and/or treating radiation injury

Publications (2)

Publication Number Publication Date
CN108392482A CN108392482A (en) 2018-08-14
CN108392482B true CN108392482B (en) 2020-03-20

Family

ID=63092342

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010063267.0A Active CN111388474B (en) 2018-03-05 2018-03-05 Application of milbexate in preparation of medicine for preventing and/or treating radiation injury
CN201810178801.5A Active CN108392482B (en) 2018-03-05 2018-03-05 β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010063267.0A Active CN111388474B (en) 2018-03-05 2018-03-05 Application of milbexate in preparation of medicine for preventing and/or treating radiation injury

Country Status (1)

Country Link
CN (2) CN111388474B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101269076A (en) * 2007-03-22 2008-09-24 中国人民解放军军事医学科学院放射与辐射医学研究所 Medicine use of beta-methoxy acrylic ester compounds as novel STAT3 restrainer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101269076A (en) * 2007-03-22 2008-09-24 中国人民解放军军事医学科学院放射与辐射医学研究所 Medicine use of beta-methoxy acrylic ester compounds as novel STAT3 restrainer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Flucrypyrim, a novel uterine relaxant, has antinociceptive and anti-inflammatory effects in vivo;Zhongtang Li, et al.;《Scientific Reports》;20170221;第7卷;1-11 *
重症急性放射病防治新药研究进展;张蕊莹 等;《国际药学研究杂志》;20160630;第43卷(第3期);431-435 *

Also Published As

Publication number Publication date
CN111388474B (en) 2022-08-02
CN111388474A (en) 2020-07-10
CN108392482A (en) 2018-08-14

Similar Documents

Publication Publication Date Title
Pollock et al. Effect of surgical stress on murine natural killer cell cytotoxicity.
Cotto et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors
JP2015163610A (en) Pharmaceutical composition protecting mammal cell from ionizing radiation-induced damage
CN104473910A (en) Pregabalin sustained release pellets and preparation method thereof
CN108392482B (en) β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury
CA2672716C (en) Novel therapeutic use for treating leukaemia
Sarumathy et al. Efficacy and safety of oral glutamine in radiation induced oral mucositis in patients with head and neck cancer
CN114028387B (en) Application of Brusatol in preparation of anti-radiation injury medicine
CN111249274B (en) Application of ginkgolide B in preparation of glioma cell activity inhibitor
WO2021023291A1 (en) Use of proflavine in treatment of lung cancers
Niu et al. Protection of esophageal multi-lineage progenitors of squamous epithelium (stem cells) from ionizing irradiation by manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy
Ronald Steriti Nutritional support for chronic myelogenous and other leukemias: a review of the scientific literature
CN108853506A (en) A kind of combination drug and application thereof for treating leukaemia
CN102125569A (en) Application of 1, 6-bisphosphate fructose in preparation of anti-cancer medicaments
RU2468802C2 (en) Combined antituberculous composition
JP5512275B2 (en) Use of trisubstituted glycerol compounds for the treatment of radiation injury
Yung et al. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas
RU2430724C2 (en) Coformulated antituberculous drug
HU217966B (en) Use of hydroxychloroquin for treatment of graft-versus-host disease
Gandola et al. Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation
KR100454200B1 (en) Germanium mixed mineral having anti-cancer activating ingredient and its use as anti-cancer medicine
Cheng Combined Radiation–Burn Injuries
CN110215460B (en) Combined drug for resisting tumors
RU2413517C1 (en) Combined antituberculous composition
Carde Hodgkin's lymphoma. II: Treatment and delayed morbidity.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant